Kornimate/medical-research-clean huggingface dataset:
investigation of physical and emotional status the elderly infected and non-infected with covid-19

Conditions: COVID-19 Pandemic

Summary: the aim of this observational study is to evaluate individuals in terms of balance, functional mobility, influences in activities of daily living, fear of covid-19, moods, quality of life parameters in order to investigate the effects of covid-19 on elderly individuals.

this study was carried out to investigate the status of elderly individuals who survived the covid-19 in terms of different parameters such as balance, functional mobility, activities of daily living, quality of life, fear of covid-19, depression. a total of 107 elderly individuals aged 65 and over were included in the study, including 52 elderly individuals who survived the covid-19 and 55 elderly individuals who non-infected covid-19. the sociodemographic information of the participants was recorded. the berg balance scale was used to evaluate the balance levels, the timed up and go test was used to evaluate the functional mobility levels, and the functional independence scale was used to evaluate the activities of daily living. the world health organization quality of life instrument-older adults module (whoqol-old) was used to evaluate the quality of life, the fear of covid-19 scale was used to evaluate the covid-19 fear levels, the geriatric depression scale was used to evaluate the symptoms of depression.

Eligibility criteria:
inclusion criteria: * being an individual aged 65 and over voluntarily to participate in the study * not having a problem affecting understanding and speaking, having the ability to walk without any help exclusion criteria: * having any musculoskeletal or neurological problem that may affect walking and balance * have a known mental problem

Keywords: geriatrics aged functional status postural balance quality of life activities of daily living fear depression covid-19
celiprolol in patients with ehlers-danlos syndrome, vascular type

Conditions: EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT; CHROMOSOME 2q31.2 DELETION SYNDROME

Summary: ehlers-danlos syndrome vascular type (eds-iv) is caused by a genetic defect of collagen type iii. patient die (median 40 yrs) of vascular complications. there is no treatment. we showed that arteries are thin and overloaded in this patients. we test the protective effect of celiprolol on cardiovascular events in a 5 years, randomized, probe design

100 patients with verified eds-iv syndrome are included. patients are randomized to either celiprolol (50 to 400 mg bid)or no treatment. patients who are not randomized enter a longitudinal survey of events. the hypothesis is a 50% reduction in the occurrence of cardiovascular events under treatment, assessed by a blinded, independent events committee.

Eligibility criteria:
inclusion criteria: * proven disease, * no betablocker at inclusion if previous cv event exclusion criteria: criteria of not inclusion for the righteous group: * patient having already presented an arterial break or a dissection and treated(handled) by bétâ-blocking(surrounding). * against indication in the use of celiprolol: * unchecked cardiac insufficiency by the treatment * cardiogenic shock * bav of 2nd and 3rd not sailed degrees * angor of prinzmetal * disease of the sine * bradycardia * pheochromocytoma untreated * low blood pressure * sentimentality in the celiprolol * antecedent of anaphylactic reaction * myasthenia * treatment by floctafenine ( idarac), sultopride ( interactions ) in these two cases, the patient can be included in the group followed by troop. criteria of not inclusion for both groups: * refusal to participate in the study. * impossibility to move. * pregnancy * woman in age to procreate without means of effective contraception.

Keywords: arteries ultrasonography ehlers danlos syndrome cardiovascular disease beta adrenergic antagonists
proteomic signature in breast cancer: correlation with tumor response to neo-adjuvant chemotherapy

Conditions: Breast Cancer

Summary: the scope of the trial is to identify proteomic signatures correlated with tumor response to neo-adjuvant chemotherapy.


Eligibility criteria:
inclusion criteria: * women aged more than 18 years * histologically proven breast carcinoma * neo-adjuvant chemotherapy with anthracyclines and/or taxanes * no prior chemotherapy * written informed consent exclusion criteria: * metastatic disease

Keywords: breast cancer neo-adjuvant chemotherapy proteomic histological response
intravesical gemcitabine instillation followed by transurethral resection for the treatment of patients with superficial bladder cancer at low risk.

Conditions: Superficial Bladder Cancer

Summary: the purpose of this study is to determine whether neoadjuvant intravesical gemcitabine is enough active in patients with a solitary, low risk superficial bladder cancer.after diagnostic urethrocystoscopy or bladder sonography, all patients will receive intravesical gemcitabine once a week during 6 weeks. two weeks after finishing antiblastic therapy, all patients will be submitted to a new cystoscopy, with tur or cold biopsies of the site of the initial lesion.


Eligibility criteria:
inclusion criteria: * primary solitary bladder tumour not exceeding 2 cm of diameter at sonography and/or at cystoscopy, judged by the investigator not muscle infiltrating and at low risk * urinary cytology negative for severe dysplasia (g3). * ecog performance status 0-1 * absence of anti-coagulant therapy or acetyl-salicylic acid chronic therapy * absence of other present or past neoplasias except for healed skin basalioma exclusion criteria: * tumours with infiltrative patterns at cystoscopy * transitional carcinoma of the upper urinary tract and prostatic urethra. * any previous or concomitant malignancy other than superficial bladder cancer with the exception of cutaneous basalioma and/or cancer of the cervix, adequately treated.
helicobacter pylori eradication in diabetic subjects with non-alcoholic fatty liver disease

Conditions: Non-alcoholic Fatty Liver Disease

Summary: the aim of study was to evaluate the effect of helicobacter pylori eradication on liver fat content, liver function tests, lipid profile, homeostasis model assessment-ir (homa-ir) index, and anthropometric measurements (body mass index and waist circumference)in diabetic subjects with non-alcoholic fatty liver disease.

helicobacter pylori (hp) antigens have been found in the liver of individuals with benign and malignant liver diseases. the role of hp in the pathogenesis of non-alcoholic fatty liver disease (nafld) is controversial. this randomized double blind clinical trial was performed in diabetic dyspeptic patients with positive antibody to hp and the evidence of fatty liver in ultrasonography. after excluding other causes, participants with persistent elevated serum aminotransferase levels were presumed to have nafld. those with nafld liver fat score greater than (-0.64) and positive urea breath test (ubt) were enrolled. they were randomly assigned to lifestyle modification alone or lifestyle modification plus hp eradication groups. quadruple therapy (omeprazole, amoxicillin, bismuth subcitrate, and clarithromycin) for hp eradication was performed in two weeks. hp eradication was documented by ubt. liver fat content, fasting serum glucose, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, triglyceride, cholesterol, high and low-density lipoprotein, homa-ir, and anthropometric measurements (body mass index and waist circumference) were checked at baseline and six weeks post-treatment.

Eligibility criteria:
inclusion criteria: * diabetic dyspeptic patients with positive antibody to h.pylori and persistent elevated aminotransferase levels with the evidence of fatty liver in ultrasonography, who were referred to a gastroenterology clinic exclusion criteria: * alcohol use (more than 20 gram per day in men and 10 gram per day in women per day), heart disease (ischemic or congestive), hepatic disease (viral hepatitis, autoimmune hepatitis, wilson disease, hemochromatosis, liver mass lesion), renal disease (serum creatinine concentration of \> 1.5 mg/dl), any severe systemic co-morbidities, neoplasm, using any hepatotoxic medication during the past 3 months, previous history of peptic ulcer, previous history of h.pylori eradication, existence of alarm signs (weight loss, dysphagia, anemia, vomiting, positive family history of gastrointestinal cancers), and pregnant or lactating women.

Keywords: steatohepatitis, helicobacter pylori, insulin resistance, alanine aminotransferase, aspartate aminotransferase,
reduced total blood loss and blood transfusion in non-septic revision knee arthroplasty using a bipolar sealer

Conditions: Total Blood Loss

Summary: to investigate if the use of a bipolar sealer for skin and capsula incision results in decreased total blood loss and/or less blood transfusion in non-septic knee arthroplasty.

in patients undergoing primary total knee arthroplasty, perioperative anemia is highly prevalent. in a systematic review, preoperative anemia was found in 24 +/- 9% and postoperative anemia in 51% +/- 10%. perioperative anemia was associated with a blood transfusion rate of 45 +/- 25%, postoperative infections, poorer physical functioning and recovery, and increased length of hospital stay (los) and mortality. although the best transfusion trigger in elective patients remains unknown, restrictive transfusion protocols are recommended and avoidance of blood transfusion if possible. the only non-systemic modality capable of reducing blood loss before it occurs is a bipolar sealer (aquamantys). by pre-incisional treatment of the soft tissue, bleeding (and potentially total blood loss and transfusion) is reduced without tissue charring. previously studies on the use of aquamantys in primary knee arthroplasty have had various outcomes, the most recent being negative while the former 3 were positive regarding reduction in blood loss, drop in hgb and transfusions. no published date exist on potential outcomes in revision knee arthroplasty where blood loss and transfusion needs exceeds that of primary total knee arthroplasty by far. aquamantys hence would theoretically benefit the most in a revision setting without the use of a tourniquet - and would be an interesting modality in modern contemporary fast-track revision if shown effective despite/on top of the use of additional blood saving modalities. the present study is therefore motivated by investigating this aspect.

Eligibility criteria:
inclusion criteria: * patients undergoing non septic knee-arthroplasty revision. * musk speak and understand danish exclusion criteria: * age below 18.

Keywords: reduction of blood loss for revisions of knee arthroplasty blood transfusions readmission bipolar sealer
radiation dose of pediatric patients during ureteroscopy

Conditions: Urolithiasis

Summary: the purpose of this study is to quantify the radiation exposure from diagnostic testing and surgical treatment during routine endourologic procedures for symptomatic urolithiasis.

routine endourologic procedures will be performed at the childrens hospital of pittsburgh by one of the investigators listed on this study. fluoroscopic radiation exposure during these procedures is used to guide the surgical devices that are used to treat the stones. the investigators will be measuring the radiation effective skin dose by two methods. first, the investigators will place two "microdot" thermal leak detectors (tld) on the patient. these devices which are the size and thickness of a dime will be within plastic bags taped to the patients body within the central focus of the fluoroscopy image. at the completion of the procedure the tld's will be transferred to the radiation safety office in oakland to be read and the dose recorded. second, a flat chamber that is integral with all fluoroscopy machines used at children's hospital will measure the dose-area product (dap) for each case which will allow us to calculate the effective dose. this device is a component of the colimeter on the arm of the x-ray machine used for fluoroscopy. it measures the radiation that is returned to the x-ray machine and calculates the dose delivered to the patient by comparing the amount delivered to the patient to the amount returned to the machine. its use is automatic when any x-rays are delivered and does not involve any manipulation of the patient or alteration of normal procedure. no additional procedures or change in duration is necessary for this study

Eligibility criteria:
inclusion criteria: * eligible subjects will be male and female volunteers of 0-18 years of age with documented urolithiasis who is undergoing a urologic procedure that utilizes fluoroscopy radiation. * the racial, gender and ethnic characteristics of the proposed subject population reflect the demographics of pittsburgh and the surrounding area and/or the population of the university of pittsburgh. * we shall attempt to recruit subjects in respective proportion to these demographics. exclusion criteria: * none
autologous platelet-rich plasma in the management of asherman syndrome

Conditions: Intrauterine Adhesion

Summary: the aim of the study is to find out the benefit of the platelet-rich plasma in preventing reformation of intrauterine adhesions after adhesiolysis in cases of asherman syndrome

patients fulfilling criteria will be randomized into three equal groups. the patients who are diagnosed previously with severe as will choose an envelope which determines the treatment method. there will be 60 envelops assigning for the groups mixed together in one box. this will ensure a randomized allocation of patients to either group of this study. hysteroscopy adhesiolysis will be done to all participants in the study. in the first group, adhesiolysis will be followed by intrauterine use of prp then insertion of intrauterine foley balloon catheter that will be inflated and left for 2 weeks. in the second group, adhesiolysis will be followed by insertion of intrauterine foley balloon catheter covered by freeze-dried amniotic graft and will be inflated and left for 2 weeks. in the third group, adhesiolysis will be followed by insertion of intrauterine foley balloon catheter that will be inflated and left for 2 weeks. all patients will be given antibiotics and hormonal treatment. also, they will be given low dose aspirin and sildenafil 50mg daily.

Eligibility criteria:
inclusion criteria: severe intrauterine synechia confirmed by hysteroscopy * age group from 20 to 40 years exclusion criteria: * hemoglobin less than 11 g/dl * platelet less than 150000/mm3 * patients taking anticoagulants * patients taking nsaid in the 15 days prior to the procedure * active cervical or uterine infection
efficacy and safety of df289 plus df277 otic solution in the treatment of middle ear infections in pediatric patients

Conditions: Acute Otitis Media

Summary: the purpose of this study is to determine if a combination of an antibiotic plus a corticosteroid is safe and effective in treating middle ear infections in children with ear tubes.


Eligibility criteria:
inclusion criteria: * 6 months to 12 years * ear tube in the ear which will be treated * otorrhea for 3 weeks or less * moderate or severe otorrhea exclusion criteria: * other ear diseases

Keywords: with tubes
exploratory study of the effects of peptide pms-001 on long-delay recall in patients with moderate to severe dementia

Conditions: Dementia

Summary: this is a single-center, randomized, double-blind, placebo-controlled study. patients will be randomly assigned to either the peptide intervention group (with dose escalation at 15mg, 30mg, 60mg, and 75mg) or the placebo control group. after learning and training, participants will receive an injection of pms-001. the efficacy and safety of the intervention will be assessed at 1 hour, 1 day, 3 days, and 1 week post-intervention. this study aims to evaluate the effects of pms-001 on improving long-delay recall in patients with moderate to severe dementia, as well as its safety profile.


Eligibility criteria:
inclusion criteria: 1. participants must be aged 60 to 80 years (inclusive) at the time of screening, regardless of gender. 2. participants must have a clinical dementia rating (cdr) total score \> 1, indicating moderate to severe dementia. 3. participants must provide written informed consent to participate in the study. exclusion criteria: 1. presence of other neurological diseases that may cause cognitive decline, such as cerebrovascular disease, encephalitis, brain tumors, traumatic brain injury, epilepsy, parkinson's disease, etc. 2. presence of metabolic diseases that may cause cognitive decline, such as anemia, thyroid dysfunction, folate and vitamin b12 deficiency, etc. 3. presence of severe psychiatric disorders, such as major depression. 4. history of carbon monoxide poisoning. 5. presence of acute or severe life-threatening diseases. 6. presence of severe visual, auditory, or language impairments that would prevent the completion of neuropsychological assessments. 7. current use of psychotropic medications or a history of substance abuse. 8. individuals with specific allergy histories, or those with a history of allergies to two or more medications, foods (such as milk), or pollen (excluding untreated, asymptomatic seasonal allergies), or known allergies to components of the study drug or similar agents.

Keywords: dementia treatment
a study to assess ct-868 and the relationship between insulin secretory response and ambient blood glucose

Conditions: Diabetes

Summary: a study to assess the effect of ct-868 and the relationship between insulin secretory response and ambient blood glucose in obese male subjects and subjects with t2dm.


Eligibility criteria:
inclusion criteria: * part 1: obese otherwise healthy males * part 2: males or females with t2d * part 1: bmi 30.0-35.0, inclusive * part 2: bmi 27.0-45.0, inclusive * 18-65 years old, inclusive * stable body weight for 2 months exclusion criteria: * significant medical history * uncontrolled hypertension * history of malignancy

Keywords: diabetes mellitus diabetes mellitus, type 2 overweight metabolic diseases body weight
thermal imaging to evaluate skin toxicity from radiotherapy

Conditions: Radiotherapy Side Effect; Radiodermatitis

Summary: a significant proportion of patients treated with whole-breast or head and neck radiotherapy will experience skin toxicity, i.e. skin dermatitis, which may lead to erythema, dry desquamation and wet desquamation. it is hypothesized that quantitative thermal imaging can be used to measure radiation-induced skin toxicity.

the aim of this study is to use quantitative thermal imaging to evaluate skin toxicity in patients treated with whole-breast or head and neck radiotherapy.

Eligibility criteria:
inclusion criteria: 1. biopsy-confirmed diagnosis of breast cancer (stage 0-iii) or head and neck cancer (all subtypes; stage i - iv) according to american joint committee on cancer staging criteria. 2. subjects must give appropriate written informed consent prior to participation in the study 3. subjects must be able and willing to comply and understand the instructions associated with the imaging procedure. 4. both men and women are eligible for participation 5. subjects must be at least 18 years of age 6. subjects must be receiving radiotherapy: 1. adjuvant radiotherapy to the whole breast or chest wall, or; 2. in the case of head and neck treatment, either as definitive treatment or adjuvantly. 7. definitive radiotherapy of the head and neck exclusion criteria: 1. subjects with any pre-existing dermatologic abnormalities (open sores, keloids, psoriasis) involving the treated breast or head and neck. 2. patients with very hairy skin surface (this does not permit measuring the heat output) 3. subjects with a current or past medical history of connective tissue disease. 4. subjects who are pregnant or lactating (which usually preclude them from radiotherapy) 5. subjects, who, in the opinion of the investigator or clinical research coordinator, may not otherwise be appropriate for inclusion into the study, such as significant anxiety, history of musculoskeletal disease which may predispose them to discomfort during the imaging/scanning period.
development of frailty prevention clinic in geriatric comprehensive clinic rscm:

Conditions: Frailty; Sarcopenia; Resistance Training

Summary: there is an increasing number of elderly population, not only in indonesia, but also in the world. with increasing of age, there is also an increasing number of elderly with sarcopenia and frailty. both of the diseases can lead to dependency, decrease quality of life, and morbidity. besides nutrition, physical activity, especially resistance training is proven to be beneficial in improving sarcopenia and frailty condition. currently in cipto mangunkusumo national hospital (rscm), there is no comprehensive frailty prevention clinic in the geriatric inpatient clinics. this research can be the base of frailty and sarcopenia treatment in rscm.


Eligibility criteria:
inclusion criteria: * patients 60 years old or orlder * categorized as pre-frail or frail based on frail criteria * is not in routine physical activity in the past 3 months * succeeded mini physical performance test with score 11 or more exclusion criteria: * cognitive disturbance (abbreviated mental test \< 8) * not consenting to join the trial

Keywords: frailty sarcopenia elderly resistance training